We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

129 hedge funds and large institutions have $973M invested in Apellis Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 45 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,855% more call options, than puts

Call options by funds: $9.03M | Put options by funds: $462K

258% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 12

61% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 28

30% more funds holding

Funds holding: 99 → 129 (+30)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.6% less ownership

Funds ownership: 64% → 63.4% (-0.6%)

5% less capital invested

Capital invested by funds: $1.03B → $973M (-$52M)

Holders
129
Holders Change
+30
Holders Change %
+30.3%
% of All Funds
2.83%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
43
Increased
45
Reduced
28
Closed
12
Calls
$9.03M
Puts
$462K
Net Calls
+$8.57M
Net Calls Change
+$8.56M

Top Buyers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
+$57.8M
2
Fidelity International
Fidelity International
Bermuda
+$30.2M
3
BC
Boxer Capital
California
+$19.3M
4
Millennium Management
Millennium Management
New York
+$18.4M
5
Morgan Stanley
Morgan Stanley
New York
+$11M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$41.7M
2
O
OrbiMed
New York
-$33M
3
Citadel Advisors
Citadel Advisors
Florida
-$16.3M
4
SAM
Sectoral Asset Management
Quebec, Canada
-$13.6M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
76
UBS Group
Switzerland
$743K -$431K -15,674 -34%
AIG
77
American International Group
New York
$735K -$5.86K -213 -0.7%
AC
78
Athanor Capital
New York
$590K +$256K +9,300 +61%
Assenagon Asset Management
79
Assenagon Asset Management
Luxembourg
$586K +$669K +24,312 New
ProShare Advisors
80
ProShare Advisors
Maryland
$548K +$13K +471 +2%
TD Asset Management
81
TD Asset Management
Ontario, Canada
$548K +$160K +5,824 +34%
MIM
82
MetLife Investment Management
New Jersey
$537K – – –
ECM
83
Endurant Capital Management
California
$537K +$613K +22,281 New
RIM
84
Regent Investment Management
Kentucky
$513K -$55K -2,000 -9%
Ameriprise
85
Ameriprise
Minnesota
$494K -$1.86M -67,670 -77%
VOYA Investment Management
86
VOYA Investment Management
Georgia
$451K – – –
CSS
87
Cubist Systematic Strategies
Connecticut
$446K +$508K +18,449 +21,705%
TCM
88
Tenor Capital Management
New York
$423K +$483K +17,548 New
MAM
89
Myriad Asset Management
Hong Kong
$422K +$483K +17,548 New
State Board of Administration of Florida Retirement System
90
State Board of Administration of Florida Retirement System
Florida
$414K – – –
MLICM
91
Metropolitan Life Insurance Company (MetLife)
New York
$389K +$84.5K +3,071 +24%
JP Morgan Chase
92
JP Morgan Chase
New York
$382K +$70.7K +2,570 +19%
B
93
Bailard
California
$361K – – –
Nomura Holdings
94
Nomura Holdings
Japan
$355K +$440K +16,000 New
HI
95
HBK Investments
Texas
$338K +$386K +14,038 New
SAM
96
Symphony Asset Management
California
$338K +$386K +14,038 New
JG
97
Jefferies Group
New York
$324K +$370K +13,429 New
LI
98
Leap Investments
Illinois
$306K +$350K +12,700 New
VEA
99
Virtus ETF Advisers
New York
$288K -$18.3K -665 -5%
AC
100
Aristeia Capital
Connecticut
$279K +$319K +11,600 New
2 3
4
5 6

APLS Hedge Fund Activity: Q3 2019 in Review

129 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2019, worth a combined $973M — down 5.1% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new APLS positions and 12 closed out — a net gain of 31 holders — while 45 added to existing stakes and 28 trimmed.

The largest buyer was HHLR Advisors, adding an estimated $57.8M. The largest seller was Wellington Management Group, cutting an estimated $41.7M.

  • 129 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2019, up from 99 in Q2 2019.
  • Funds reported $973M of Apellis Pharmaceuticals stock for Q3 2019, down 5.1% quarter-over-quarter.
  • 43 funds opened new Apellis Pharmaceuticals positions in Q3 2019 and 12 closed out, a net change of +31 holders.
  • The largest Apellis Pharmaceuticals buyer in Q3 2019 was HHLR Advisors, an estimated $57.8M added.
  • The largest Apellis Pharmaceuticals seller in Q3 2019 was Wellington Management Group, an estimated $41.7M sold.

Based on aggregated 13F filings for Q3 2019.